|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
The pharmaceutical industry has been moving away from the traditional research-driven business model to one that is motivated by the marketing of major branded products. Compelled by the need to create bestseller products and then defend their sales post-patent expiry, pharmaceutical companies are increasingly using the power of branding to capture the hearts and minds of the public.
Colours are often the central element of a product's branding, and reputation can be built on colour alone. By way of example, AstraZeneca's Losec was promoted as the 'purple pill' in advertisements, and the replacement for Losec - Nexium - is the same colour and is referred to as 'the new purple pill'. Also, in advertisements for Pfizer's Viagra, Bob Dole refers to the pill as his 'little blue friend'. So to what extent can companies protect the colours of their products and packaging as national trademarks in the UK, or alternatively as community trademarks (CTMs)?
This article will briefly discuss the advantages of registered Trademarks and the approach taken by the UK Trade Marks Registry and the Office of Harmonisation for the Internal Market (OHIM) (which grants CTMs) towards the registration of colours as trademarks. It will then discuss the recent European Court of Justice (ECJ) decision in Libertel Groep BV v Benelux-Merkenbureau (1), which will have an important impact on the way in which EU trademark offices will approach applications to register colour marks in the future and consequently on the way colours will be used in the pharmaceutical industry as source identifiers.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations
Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >> |
|
 |
White Papers |
 |
|
7 Common Myths about QP Training Debunked: A Guide for Senior Managers
RSSL
The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >> |
|
 |
Industry Events |
 |
PDA Europe Annual Meeting 2019
24 June 2019, Hilton Amsterdam
Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >> |
|
|
